E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder — Stella

Home/Opioid Use Disorder/

View on ClinicalTrials.gov

Recruiting

Back to Opioid Use Disorder trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United States

NYU Langone Health, New York, New York

Albert Einstein College of Medicine, The Bronx, New York

Key details

Phase

Safety & dosing

Sponsor

NYU Langone Health

Collaborators

National Institutes of Health (NIH)

Enrollment target

~302 participants

Started

August 2024

Primary completion

November 2026

Age range

21 Years – 75 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.